733 related items for PubMed ID: 20367536
1. Fingolimod for relapsing multiple sclerosis: an update.
Horga A, Castilló J, Montalban X.
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[Abstract] [Full Text] [Related]
2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
[Abstract] [Full Text] [Related]
3.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
4. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B, Ross AP, Tobias K.
Int J Clin Pract; 2011 Aug 04; 65(8):887-95. PubMed ID: 21679286
[Abstract] [Full Text] [Related]
5. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.
Expert Rev Neurother; 2011 Feb 04; 11(2):165-83. PubMed ID: 21158700
[Abstract] [Full Text] [Related]
6. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA, Weinstock-Guttman B.
Adv Ther; 2011 Apr 04; 28(4):270-8. PubMed ID: 21394595
[Abstract] [Full Text] [Related]
7. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Vasiliou S.
Drugs Today (Barc); 2010 May 04; 46(5):315-25. PubMed ID: 20517533
[Abstract] [Full Text] [Related]
8. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[Abstract] [Full Text] [Related]
9. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ.
CNS Drugs; 2011 Aug 22; 25(8):673-98. PubMed ID: 21790210
[Abstract] [Full Text] [Related]
10. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L, FTY720D2201 Study Group.
Mult Scler; 2010 Feb 22; 16(2):197-207. PubMed ID: 20028707
[Abstract] [Full Text] [Related]
11. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA, Kantesaria PP, McDevitt LM.
Ann Pharmacother; 2007 Oct 22; 41(10):1660-8. PubMed ID: 17785617
[Abstract] [Full Text] [Related]
12. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW, Choi JW, Chun J.
Arch Pharm Res; 2010 Oct 22; 33(10):1567-74. PubMed ID: 21052934
[Abstract] [Full Text] [Related]
13. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD, Jones DE, Goldman MD.
Expert Opin Drug Saf; 2014 Jul 22; 13(7):989-98. PubMed ID: 24935480
[Abstract] [Full Text] [Related]
14. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K, Adachi K.
Future Med Chem; 2012 Apr 22; 4(6):771-81. PubMed ID: 22530640
[Abstract] [Full Text] [Related]
15. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.
Pharmacol Ther; 2008 Jan 22; 117(1):77-93. PubMed ID: 17961662
[Abstract] [Full Text] [Related]
16. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
Tanasescu R, Constantinescu CS.
Expert Opin Drug Metab Toxicol; 2014 Apr 22; 10(4):621-30. PubMed ID: 24579791
[Abstract] [Full Text] [Related]
17. FTY720 (fingolimod) for relapsing multiple sclerosis.
Horga A, Montalban X.
Expert Rev Neurother; 2008 May 22; 8(5):699-714. PubMed ID: 18457527
[Abstract] [Full Text] [Related]
18. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP.
Clin Immunol; 2012 Jan 22; 142(1):15-24. PubMed ID: 21669553
[Abstract] [Full Text] [Related]
19. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Széplaki G, Merkely B.
Ideggyogy Sz; 2012 Nov 30; 65(11-12):369-76. PubMed ID: 23289171
[Abstract] [Full Text] [Related]
20. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
Lancet Neurol; 2014 Jun 30; 13(6):545-56. PubMed ID: 24685276
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
